Biotech & pharma
India sees early competition in semaglutide as drugmakers prepare lower-cost versions
By Axel Miller | 20 Mar 2026
Indian pharmaceutical companies are exploring lower-cost semaglutide options, aiming to expand access to diabetes and obesity treatments.
Novartis to buy breast cancer drug candidate from Synnovation in up to $3 billion deal
By Axel Miller | 20 Mar 2026
Novartis will acquire a breast cancer drug candidate from Synnovation Therapeutics in a deal worth up to $3 billion, boosting its oncology pipeline.
Zydus and Lupin partner to co-market semaglutide injections in India
By Cygnus | 17 Mar 2026
Zydus and Lupin sign a licensing deal to co-market semaglutide injections in India, introducing a reusable pen device for diabetes and weight-management therapy.
CDSCO warns pharma firms over ‘surrogate’ ads for obesity drugs
By Axel Miller | 12 Mar 2026
CDSCO warns pharma firms against indirect promotion of GLP-1 weight-loss drugs ahead of generic launches.
Novo Nordisk signs up to $2.1 billion deal with Vivtex to develop oral obesity therapies
By Cygnus | 25 Feb 2026
Novo Nordisk signed a partnership worth up to $2.1 billion with Vivtex to develop oral treatments for obesity and diabetes.
Indian Patent Office rejects AbbVie patent bid for cancer drug Venetoclax; generics may enter market
By Cygnus | 23 Jan 2026
The Indian Patent Office rejected AbbVie’s patent application for cancer drug Venetoclax (Venclexta), a decision expected to ease the entry of lower-cost generics.
Sun Pharma Weighs $10 Billion Takeover of Organon to Expand US Footprint
By Cygnus | 19 Jan 2026
Sun Pharma is evaluating a ~$10B acquisition of Organon to expand its U.S. footprint in women's health and biosimilars, according to reports.
The $280 Ozempic: How a Canadian Bridge to India is Slashing U.S. Weight-Loss Costs
By Axel Miller | 07 Jan 2026
U.S. patients are bypassing $1,100 retail prices with $280 India-sourced Ozempic pens via Canada. A deep dive into the 2026 semaglutide supply chain.
Glenmark Pharma Hits Record High on Landmark AbbVie Licensing Deal
By Cygnus | 11 Jul 2025
Glenmark Pharmaceuticals shares rallied 10% on Friday to reach a record high after its biotech subsidiary signed a significant licensing agreement with U.S. drugmaker AbbVie.
India achieves breakthrough in gene therapy for Haemophilia
25 Apr 2025
Bengaluru’s BRIC-inStem institute has achieved a breakthrough in gene therapy for Haemophilia, union minister for science and technology, Dr Jitendra Singh said
Bayer seeks legal cover in US for its Roundup weedkiller sales
08 Mar 2025
German pharmaceutical and biotechnology group, Bayer, has told the US government that it would have to stop selling its Roundup weedkiller in the United States
Balrampur Chini sets up India's first biopolymer manufacturing unit in Uttar Pradesh
24 Feb 2025
Balrampur Chini Mills Ltd (BCML), one of the largest sugar mills in the country, is diversifying further by venturing into the production of Poly Lactic Acid (PLA)
Scientists at Mohali’s Nano Science Institute identify common biomarker for cancer detection
21 Feb 2025
A research team at the Institute of Nano Science and Technology (INST), Mohali has identified a common biomarker for early detection of a range of cancers
.webp)
PM Modi hails Genome project as data of 10,000 Indians go live
09 Jan 2025
Prime Minister Narendra Modi on Thursday announced the completion of the Genome India project, which makes available database of 10,000 Indians
Pune’s Agarkar Institute develops novel molecule for treating Alzheimer’s disease
26 Oct 2024
Scientists from Agharkar Research Institute, Pune, an autonomous institute of Department of Science and Technology,
Victor Ambros and Gary Ruvkun of US win Medicine Nobel for discovery of microRNA
08 Oct 2024
Victor Ambros, a professor at the Harvard Medical School and Gary Ruvkun, an investigator with Massachusetts General Hospital, jointly won the 2024 Nobel Prize in Physiology or Medicine.
Western drugmakers pivot to India as tensions with China prompt supply chain shifts
27 Nov 2023
In a strategic move to reduce dependence on Chinese contractors in drug production, global pharmaceutical companies are turning to Indian manufacturers.
British Airways joins Project Speedbird for cleaner aviation fuel
17 Nov 2023
The project is supported by the British government with a £9 million grant from the Advanced Fuels Fund (AFF).
Merck and Daiichi partner on a $5.5 billion deal for cancer therapy development
20 Oct 2023
The American pharmaceutical company Merck will start a joint venture with Daiichi Sankyo to develop three of its candidate cancer drugs.
U.S. pharmacy store Rite Aid files for bankruptcy protection amid several lawsuits
16 Oct 2023
Rite Aid filed for Chapter 11 bankruptcy on Sunday, October 15, 2023, taking a step to suspend the lawsuits against the drugstore chain related to its alleged
CRISIL predicts an 8-10% revenue growth for Indian pharma industry in current fiscal year
11 Sep 2023
According to a report, the Indian pharmaceutical industry is expected to achieve 8 to 10 per cent revenue growth in the current fiscal year.
Accusations from Iowa farmers: China allegedly stealing American seeds
08 Aug 2023
Farmers in Iowa are making accusations against the Chinese state, alleging the theft of invaluable seed samples from America.
Latest articles
Featured articles
.webp)
Artemis II and the economic outlook for lunar infrastructure
By Axel Miller | 01 Apr 2026
Artemis II will test deep-space systems and support future lunar missions, shaping the next phase of the global space economy.
Synthetic diplomacy: The $50 billion mirage and the new era of market-moving deepfakes
By Cygnus | 30 Mar 2026
Synthetic diplomacy shows how deepfakes could trigger market volatility, highlighting the growing need for verification in global financial systems.
AI war shifts gears: chips, drones reshape global power
By Cygnus | 27 Mar 2026
AI competition is shifting as chips, drones and supply chains reshape global power, impacting tech, defense and business strategies.
Trump’s Iran strike delay lifts markets, but risks remain elevated
By Axel Miller | 24 Mar 2026
Trump’s Iran strike delay eased market fears, sending oil lower and lifting Sensex. Risks remain as geopolitical tensions continue.
The rise of the ‘ghost executive’: how autonomous AI agents are entering the C-suite
By Cygnus | 17 Mar 2026
Autonomous AI agents are influencing business decisions and reshaping leadership structures as companies adopt agentic AI systems in 2026.
The sky is closing: The end of the global crossroads
By Axel Miller | 16 Mar 2026
Middle East airspace disruptions are forcing airlines to reroute global flights, raising costs and reshaping aviation networks in 2026.
Living in the “New Gulf”: how conflict is reshaping cities and infrastructure
By Cygnus | 16 Mar 2026
Gulf states are redesigning infrastructure, air defenses and aviation networks as regional tensions reshape urban resilience strategies.
The Petro-Tech Pivot: Why Your Next Phone Is Built on Shifting Sands
By Cygnus | 12 Mar 2026
Rising crude prices are reshaping electronics manufacturing as petrochemical costs drive pressure across the global tech supply chain.
Hardened compute: The rise of the data bunker
By Axel Miller | 11 Mar 2026
Explore how AI demand and geopolitical risk are driving investment in fortified data centers worldwide.
